{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-038053","form_type":"8-K","ticker":null,"cik":"0001850838","company_name":"Omega Therapeutics, Inc.","filed_at":"2024-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.011408+00:00","generated_at":"2026-06-04T06:34:27.306610+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Omega Therapeutics reports FY 2023 net loss $97.4M; cuts headcount 35%, extends cash runway to Q1 2025","bullets":["Cash, equivalents and marketable securities $73.4M as of Dec. 31, 2023; expected to fund operations into Q1 2025.","OTX-2002 in HCC showed 80% disease control rate (4/5) in early cohorts; Cohort 5 (0.3 mg/kg) opened in March 2024.","Novo Nordisk collaboration for obesity: up to $532M in milestones plus tiered royalties; target enhances thermogenesis.","R&D expense $77.2M in 2023 vs $81.2M in 2022; net loss $97.4M vs $102.7M; headcount reduced ~35%.","Prioritized programs: OTX-2101 (NSCLC), HNF4A (liver regeneration), obesity controller; expect next clinical data mid-2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-038053","json":"https://secwatch.observer/filing/0000950170-24-038053.json","markdown":"https://secwatch.observer/filing/0000950170-24-038053.md","text":"https://secwatch.observer/filing/0000950170-24-038053.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850838/000095017024038053/0000950170-24-038053-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850838/000095017024038053/omga-20240328.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T06:34:27.306610+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"47906840879d42ccf24c7fddcbd15cfecedfd209","claim":"Omega Therapeutics, Inc. reported financial results for for the fourth quarter and full year ended December 31, 2023.","evidence_excerpt":"Omega Therapeutics, Inc. (the “Company”) issued a press release announcing financial results for the quarter and year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1850838/000095017024038053/0000950170-24-038053-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"for the fourth quarter and full year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}